Vincerx Pharma (NASDAQ:VINC) just reported results for the fourth quarter of 2023. Vincerx Pharma reported earnings per share of -23 cents. This was above the analyst estimate for EPS of -37 cents.

In a turbulent market environment, VINC stock has reached its 52-week low, trading at $1.62, with technical indicators from InvestingPro showing the stock in oversold territory. This price level ...

US Stocks Likely To Open Higher As Wall Street Watches Trump Tariff Talks: 'March, April, May Tend To Be Solid Months In Post-Election Years,' Says Expert US. stock futures rose on Monday ...

SAN MATEO, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC) today announced that the previously signed binding Term Sheet between Vincerx, Oqory, Inc., and Vivasor, Inc.

Nasdaq provides visual representation of analyst expected earnings growth. Read our earnings report guide before you consider the forecast information when making investment decisions. Visit the ...

16:00 EST Vincerx Pharma (VINC) Inc trading halted, news pending See what stocks are receiving Strong Buy ratings from top-rated analysts. Filter, analyze, and streamline your search for investmen ...

Investing.com – U.S. stocks were higher after the close on Tuesday, as gains in the Oil & Gas, Technology and Basic Materials ...